In particular, our study shows that KDS2010, a recently developed reversible MAO-B inhibitor, significantly ameliorates joint inflammation and cognitive impairment by ameliorating the increase in astrocytic GABA, suggesting that MAO-B is an important therapeutic target in RA (Supplementary Fig. 6). The gene discussed is MAOB; the disease is rheumatoid arthritis.